Trajectories of allergic diseases in children: Destination unknown?

IF 4.5
Birgit Kalb, Ekaterina Khaleva, Mattia Giovannini, Karine Adel-Patient, Flore Amat, Stefania Arasi, Susanne Lau, Antonio Nieto, Bianca Schaub, Marie Standl, Jonathan O'B Hourihane, Philippe Eigenmann, Antoine Deschildre
{"title":"Trajectories of allergic diseases in children: Destination unknown?","authors":"Birgit Kalb, Ekaterina Khaleva, Mattia Giovannini, Karine Adel-Patient, Flore Amat, Stefania Arasi, Susanne Lau, Antonio Nieto, Bianca Schaub, Marie Standl, Jonathan O'B Hourihane, Philippe Eigenmann, Antoine Deschildre","doi":"10.1111/pai.70131","DOIUrl":null,"url":null,"abstract":"<p><p>The trajectories of allergic diseases represent one of the most currently debated topics both when referred to childhood and likewise adulthood. Data from cohorts show their heterogeneity as well as the key role of genetic and environmental factors. More insight has been recently provided in the pathophysiological mechanisms underlying the development and amplification of T2 (hyper)inflammation. Recent data support the hypothesis of associated allergic diseases (multimorbidity) reflecting, at a given time and in given organ(s)/tissue(s), the expression of the same favorable predisposition. In particular, the impairment of the epithelial barrier, especially in subjects genetically predisposed, and the dysregulation of the host's microbiome promote the onset of allergic diseases and multimorbidity, their persistence and/or severity. These findings challenge the classical theory of the atopic march with a temporal sequence characterized by the transition from one disease (eczema) to another (food allergy, airway allergic diseases). A better understanding of the diversity of disease trajectories and the underpinning mechanisms is crucial for prevention and identification of children at risk of a \"unfavorable trajectory\" (early intervention, i.e., early primary or secondary prevention), for a personalized therapeutic approach based on identification of specific endotypes, and, therefore, addressing specific pathophysiological pathways (treat to target strategies). In the perspective of the so-called \"remission\" and \"treatment-induced-remission\", the whole spectrum of the long-term consequences of the disease(s) including their treatment has to be considered. The concept of disease modifying treatment able to interfere with their trajectories and overall long-term induced morbidity is emerging.</p>","PeriodicalId":520742,"journal":{"name":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","volume":"36 7","pages":"e70131"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/pai.70131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The trajectories of allergic diseases represent one of the most currently debated topics both when referred to childhood and likewise adulthood. Data from cohorts show their heterogeneity as well as the key role of genetic and environmental factors. More insight has been recently provided in the pathophysiological mechanisms underlying the development and amplification of T2 (hyper)inflammation. Recent data support the hypothesis of associated allergic diseases (multimorbidity) reflecting, at a given time and in given organ(s)/tissue(s), the expression of the same favorable predisposition. In particular, the impairment of the epithelial barrier, especially in subjects genetically predisposed, and the dysregulation of the host's microbiome promote the onset of allergic diseases and multimorbidity, their persistence and/or severity. These findings challenge the classical theory of the atopic march with a temporal sequence characterized by the transition from one disease (eczema) to another (food allergy, airway allergic diseases). A better understanding of the diversity of disease trajectories and the underpinning mechanisms is crucial for prevention and identification of children at risk of a "unfavorable trajectory" (early intervention, i.e., early primary or secondary prevention), for a personalized therapeutic approach based on identification of specific endotypes, and, therefore, addressing specific pathophysiological pathways (treat to target strategies). In the perspective of the so-called "remission" and "treatment-induced-remission", the whole spectrum of the long-term consequences of the disease(s) including their treatment has to be considered. The concept of disease modifying treatment able to interfere with their trajectories and overall long-term induced morbidity is emerging.

儿童过敏性疾病的发展轨迹:目的地未知?
过敏性疾病的发展轨迹是目前最具争议的话题之一,无论是在儿童时期还是成年时期。来自队列的数据显示了它们的异质性以及遗传和环境因素的关键作用。最近对T2(过度)炎症发生和扩大的病理生理机制有了更多的了解。最近的数据支持相关过敏性疾病(多病)的假设,反映了在特定时间和特定器官/组织中相同的有利易感性的表达。特别是,上皮屏障的损伤,特别是在遗传易感的受试者中,以及宿主微生物组的失调,促进了过敏性疾病和多病的发生,其持久性和/或严重性。这些发现挑战了特应性进展的经典理论,该理论具有从一种疾病(湿疹)过渡到另一种疾病(食物过敏,气道变态反应性疾病)的时间序列。更好地了解疾病轨迹的多样性和基本机制对于预防和识别处于“不利轨迹”风险的儿童(早期干预,即早期一级或二级预防),以及基于识别特定内型的个性化治疗方法至关重要,因此,解决特定的病理生理途径(从治疗到目标策略)。从所谓的“缓解”和“治疗引起的缓解”的角度来看,必须考虑疾病的整个长期后果,包括其治疗。能够干扰其轨迹和总体长期诱发发病率的疾病修饰治疗的概念正在出现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信